Table 1.
Characteristics of patients with centrally-confirmed TNBC in IBCSG Trial 22-00 overall and according to TILs (LPBC) status
| Characteristics | Total (n=647) |
Non-LPBC (n=528) |
LPBC (n=119) |
|
|---|---|---|---|---|
| Median follow-up, years | 6.9 (6.6 to 7.2) | 6.8 (6.6 to 7) | 8.0 (6.9 to 9.0) | |
| Treatment assignment, N (%) | CMM | 340 (53) | 270 (51) | 70 (59) |
| OBS | 307 (47) | 258 (49) | 49 (41) | |
| Premenopausal, N (%) | 289 (45) | 223 (42) | 66 (55) | |
| Induction chemotherapy, N (%) | Anthracycline+Taxanes ±CMF | 171 (26) | 149 (28) | 22 (18) |
| Anthracycline±CMF | 367 (57) | 293 (55) | 74 (62) | |
| CMF | 109 (17) | 86 (16) | 23 (19) | |
| Age at randomization (yrs) | Median (IQR) | 52 (44,59) | 53 (44,60) | 49 (41,56) |
| <40 | 88 (14) | 64 (12) | 24 (20) | |
| 40-<50 | 185 (29) | 147 (28) | 38 (32) | |
| 50-<60 | 217 (34) | 180 (34) | 37 (31) | |
| >=60 | 157 (24) | 137 (26) | 20 (17) | |
| White race, N (%) | 626 (97) | 511 (97) | 115 (97) | |
| Nodal status, N (%) | N0 | 370 (57) | 290 (55) | 80 (68) |
| N+ 1-3 | 171 (27) | 144 (27) | 27 (23) | |
| N+ >=4 | 103 (16) | 92 (17) | 11 (9) | |
| Unknown | 3 | 2 | 1 | |
| Tumor size, N (%) | T1 (0-2 cm) | 291 (45) | 230 (44) | 61 (51) |
| T2 (>2-5 cm) | 329 (51) | 272 (52) | 57 (48) | |
| T3 (>5 cm) | 27 (4) | 26 (5) | 1 (1) | |
| Tumor grade (CPR+local), N (%) | 1 | 3 (0) | 3 (1) | 0 (0) |
| 2 | 76 (12) | 70 (13) | 6 (5) | |
| 3 | 568 (88) | 455 (86) | 113 (95) | |
| Histology by CPR, N (%) | Ductal | 604 (93) | 488 (92) | 116 (97) |
| Lobular | 5 (1) | 5 (1) | 0 (0) | |
| Other/unknown history | 38 (6) | 35 (7) | 3 (3) | |
| Ki-67 labeling index (CPR) | Median (IQR) | 45 (31,65) | 45 (30,65) | 54 (40,75) |
| Breast-conserving surgery, N (%) | 513 (79) | 412 (78) | 101 (85) | |
| TILs score (% of cells) | Median (IQR) | 18 (8,40) | 14 (6,25) | 60 (55,70) |
Abbreviations: TILs: tumor-infiltrating lymphocytes; LPBC: Lymphocyte-predominant breast cancer (TILs score ≥50%); CPR: central pathology review; IQR: inter-quartile range